{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:51:23Z","timestamp":1794671483528,"version":"4.9.1"},"reference-count":63,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T00:00:00Z","timestamp":1431734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    This document provides guidance on the use of valproate in girls and women of childbearing age from a joint Task Force of the Commission on European Affairs of the International League Against Epilepsy (\n                    <jats:styled-content style=\"fixed-case\">CEA<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">ILAE<\/jats:styled-content>\n                    ) and the European Academy of Neurology (\n                    <jats:styled-content style=\"fixed-case\">EAN<\/jats:styled-content>\n                    ), following strengthened warnings from the Coordination Group for Mutual Recognition and Decentralised Procedures\u2010Human (\n                    <jats:styled-content style=\"fixed-case\">CMD<\/jats:styled-content>\n                    h) of the European Medicines Agency (\n                    <jats:styled-content style=\"fixed-case\">EMA<\/jats:styled-content>\n                    ), which highlight the risk of malformations and developmental problems in infants who are exposed to valproate in the womb. To produce these recommendations, the Task Force has considered teratogenic risks associated with use of valproate and treatment alternatives, the importance of seizure control and of patient and fetal risks with seizures, and the effectiveness of valproate and treatment alternatives in the treatment of different epilepsies. The Task Force's recommendations include the following: (1) Where possible, valproate should be avoided in women of childbearing potential. (2) The choice of treatment for girls and women of childbearing potential should be based on a shared decision between clinician and patient, and where appropriate, the patient's representatives. Discussions should include a careful risk\u2013benefit assessment of reasonable treatment options for the patient's seizure or epilepsy type. (3) For seizure (or epilepsy) types where valproate is the most effective treatment, the risks and benefits of valproate and other treatment alternatives should be discussed. (4) Valproate should not be prescribed as a first\u2010line treatment for focal epilepsy. (5) Valproate may be offered as a first\u2010line treatment for epilepsy syndromes where it is the most effective treatment, including idiopathic (genetic) generalized syndromes associated with tonic\u2013clonic seizures. (6) Valproate may be offered as a first\u2010line treatment in\u00a0situations where pregnancy is highly unlikely (e.g., significant intellectual or physical disability). (7) Women and girls taking valproate require regular follow\u2010up for ongoing consideration of the most appropriate treatment regimen.\n                  <\/jats:p>","DOI":"10.1111\/epi.13021","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T02:29:31Z","timestamp":1428460171000},"page":"1006-1019","source":"Crossref","is-referenced-by-count":218,"title":["Valproate in the treatment of epilepsy in girls and women of childbearing potential"],"prefix":"10.1111","volume":"56","author":[{"given":"Torbj\u00f6rn","family":"Tomson","sequence":"first","affiliation":[{"name":"Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Marson","sequence":"additional","affiliation":[{"name":"Department Molecular and Clinical Pharmacology University of Liverpool Liverpool United Kingdom"},{"name":"The Walton Centre NHS Foundation Trust Liverpool United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Boon","sequence":"additional","affiliation":[{"name":"Reference Center for Refractory Epilepsy Ghent University Hospital Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Paola","family":"Canevini","sequence":"additional","affiliation":[{"name":"Epilepsy Center Department of Health Sciences San Paolo Hospital University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Covanis","sequence":"additional","affiliation":[{"name":"Department of Neurology The Children Hospital \u201cAgia Sophia\u201d Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eija","family":"Gaily","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology Children's Hospital University of Helsinki and Helsinki University Hospital Helsinki Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetta","family":"K\u00e4lvi\u00e4inen","sequence":"additional","affiliation":[{"name":"Department of Neurology School of Medicine University of Eastern Finland Kuopio Finland"},{"name":"Kuopio Epilepsy Center Kuopio University Hospital Kuopio Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[{"name":"Department of Neurology Christian Doppler Klinik Paracelsus Medical University Salzburg Salzburg Austria"},{"name":"Centre for Cognitive Neuroscience Salzburg Austria"},{"name":"Department of Public Health and Health Technology Assessment UMIT \u2013 Health &amp; Life Sciences University Hall in Tirol Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,5,16]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"European Medicines Agency.Assessment Report. Procedure Under Article 31 of Directive 2001\/83\/EC Resulting from Pharmacovigilance Data.2014. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Referrals_document\/Valproate_and_related_substances_31\/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee\/WC500177352.pdf. Accessed April 2015."},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(85)90081-X"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2012.01.005"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70107-7"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70323-X"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.04.022"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182574f39"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306318"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-7239-x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70103-5"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31827f0874"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000318293.28278.33"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01480.x"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(199911)46:5<739::AID-ANA9>3.0.CO;2-2"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(98)00084-9"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000163771.96962.1F"},{"key":"e_1_2_12_18_1","first-page":"CD010236","article-title":"Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child","author":"Bromley R","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001182"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000030"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.06.014"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2013.08.001"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2270"},{"key":"e_1_2_12_24_1","first-page":"CD003032","article-title":"Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents","author":"Posner EB","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.40903.x"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902014"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60461-9"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306040"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02976.x"},{"key":"e_1_2_12_30_1","first-page":"CD001030","article-title":"Carbamazepine versus valproate monotherapy for epilepsy","author":"Marson AG","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_31_1","first-page":"CD001769","article-title":"Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic\u2010clonic seizures","author":"Nolan SJ","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-34"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-300376"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2012.10.020"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.03.003"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000297512.18364.40"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1982.tb05085.x"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1987.tb05769.x"},{"key":"e_1_2_12_39_1","first-page":"75","article-title":"The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies","volume":"75","author":"Nicolson A","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0387-7604(99)00113-8"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02952.x"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01194.x"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2004.05.004"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-014-7536-z"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12014"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2009.176990"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01464.x"},{"key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1684\/epd.2007.0144","article-title":"Treatment of pediatric epilepsy: European expert opinion, 2007","volume":"9","author":"Wheless JW","year":"2007","journal-title":"Epileptic Disord"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02522.x"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.11.011"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0521-1"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/1059-1311(92)90038-3"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12321"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00080-6"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620110-00004"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-33675"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02578.x"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(05)70043-0"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-014-0292-7"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03007.x"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03157-3"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0857-3"},{"key":"e_1_2_12_63_1","first-page":"1175","article-title":"Randomised study of antiepileptic drug withdrawal in patients in remission","volume":"337","author":"MRC Antiepileptic Drug Withdrawal Study Group","year":"1991","journal-title":"Lancet"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.306.6889.1374"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.13021","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.13021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T03:52:30Z","timestamp":1717818750000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.13021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,16]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/epi.13021"],"URL":"https:\/\/doi.org\/10.1111\/epi.13021","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,16]]}}}